期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 204, 期 1, 页码 191-201出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20061631
关键词
-
资金
- NIAID NIH HHS [AI 51573, P01 AI051573] Funding Source: Medline
- NIDDK NIH HHS [K01 DK071586, 5K01DK071586] Funding Source: Medline
Most treatments that prevent autoimmune diabetes in nonobese diabetic ( NOD) mice require intervention at early pathogenic stages, when insulitis is first developing. We tested whether dendritic cell (DC)-expanded, islet antigen-specific CD4(+) CD25(+) suppressor T cells could treat diabetes at later stages of disease, when most of the insulin-producing islet.. cells had been destroyed by infiltrating lymphocytes. CD4(+) CD25(+) CD62L(+) regulatory T cells (T reg cells) from BDC2.5 T cell receptor transgenic mice were expanded with antigen-pulsed DCs and IL-2, and were then injected into NOD mice. A single dose of as few as 5 x 10(4) of these islet-specific T reg cells blocked diabetes development in prediabetic 13-wk-old NOD mice. The T reg cells also induced long-lasting reversal of hyperglycemia in 50% of mice in which overt diabetes had developed. Successfully treated diabetic mice had similar responses to glucose challenge compared with nondiabetic NOD mice. The successfully treated mice retained diabetogenic T cells, but also had substantially increased Foxp3(+) cells in draining pancreatic lymph nodes. However, these Foxp3(+) cells were derived from the recipient mice and not the injected T reg cells, suggesting a role for endogenous T reg cells in maintaining tolerance after treatment. Therefore, inoculation of DC-expanded, antigen-specific suppressor T cells has considerable efficacy in ameliorating ongoing diabetes in NOD mice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据